Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lung Transplants
Research findings from F. Ruberto et al update understanding of lung transplants
July 13th, 2009
According to recent research published in the journal Transplantation Proceedings, "Primary graft dysfunction (PGD) is a syndrome that may occur after lung transplantation. In some cases of severe PGD, conventional therapies like ventilatory support, administration of inhaled nitric oxide (iNO), and surfactant and intravenous prostacyclins are inadequate to achieve adequate gas exchange." "The only lifesaving option is to use an extracorporeal membrane oxygenator. The Decapsmart is a new venovenous, low-flow extracorporeal device to removal carbon dioxide (CO2). It does not need a specialized staff. Herein we have presented a case report of a patient who...
Source: Biotech Business Week (2009-07-13)
|
